Brolucizumab (Beovu®) accepted for use within NHS Scotland

Brolucizumab intravitreal injection is approved for use in adults for neovascular (wet) age-related macular degeneration based on non-inferiority of brolucizumab vs another anti-vascular endothelial growth factor medicine for mean change in best corrected visual acuity.

Source:

Scottish Medicines Consortium